Novoglia, Inc.

Irvine, CA · Founded 2020 · CIK 0001873404 · Biotech · Private

Induced pluripotent stem cell-derived microglia cells for transplantation to treat microgliopathies

Grants
$400K
1 award
Sector median: 1
Raised
$37M
2 Form D · Jun 2025
16 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease$399,859
Private capital raisedForm D · SEC$24,304,480
Private capital raisedForm D · SEC$12,999,997
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1210VIVASC THERAPEUTICS INC——
1211AUGMENTA BIOWORKS, INC.——
1212Dianomi Therapeutics, Inc.—$185K
1213Novoglia, Inc.—$37M
1214Matrubials, Inc.——
1215MADRIGAL PHARMACEUTICALS, INC.—$35M
1216OS Therapies Inc—$30M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Jeffrey BirdDirector
  • Kim KamdarDirector
  • Keith LoebnerDirector
  • Michael SpeiserDirector
  • Robert SpitaleDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.